Continuous Manufacturing CordenPharma

January 12, 2019

Privately owned industrial holding, focused on midsized chemicals & pharmaceutical businesses ,Opportunities of consolidation and outsourcing in chemicals and pharmaceuticals , Inception in 2005  29 manufacturing facilities with approximately 6,000 employees in Europe and the United States , Total sales of approx. € 2 billion.

Spotlight

Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia’s global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia associated with chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing.

OTHER WHITEPAPERS
news image

CHEMICAL INHIBITORS TO RAS ONCOPROTEINS:CURRENT LANDSCAPE AND FUTURE OPPORTUNITIES

whitePaper | June 21, 2022

RAS is the most frequently mutated gene family in human cancers that have been considered “undruggable” due to the elusive nature of RAS inhibitors.

Read More
news image

WHAT‘S NEW WITH FLARING IN 2022

whitePaper | September 1, 2022

Without exception, all industries are facing major challenges due to the volatile business environment in which we’ve all been operating since 2020.

Read More
news image

How clumped isotopes drive a deeper understanding of petrochemical processes

whitePaper | October 12, 2022

The degree of “clumping” of heavy isotopes in molecules is solely temperature dependent in thermodynamic equilibrium

Read More
news image

Green Chemistry and Contract Synthesis – a Contradiction?

whitePaper | June 17, 2021

The topic of green chemistry is now also a challenge for contract synthesis suppliers. This is because more and more manufacturers of shampoos, detergents, paints, packaging and other consumer products are becoming increasingly concerned about the ecological footprint of their products. The trend is being fueled by consumers, who are increasingly prepared to spend more money on products that are better for the environment. But the political environment is also exerting major pressure on companies.

Read More
news image

WORLD SCALECRUDE TO OLEFINS

whitePaper | December 1, 2022

The Crude-to-Chemicals project is designed for world-scale petrochemicals production to deliver a flexible, bankable, and sustainable free-market investment. Through strong cooperation with the customer, Honeywell UOP has developed a configuration that enables 100% net olefins derived products.

Read More
news image

Validation of Titration Methods

whitePaper | September 8, 2022

The quality of your product depends on the analyses performed in quality control. That is why you rely on first-rate analytical instruments for the most accurate and precise results, and product quality

Read More

Spotlight

Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Akebia’s lead product candidate, vadadustat, is an investigational oral therapy in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia’s global Phase 3 program for vadadustat, which includes the PRO2TECT studies for non-dialysis patients with anemia associated with chronic kidney disease and the INNO2VATE studies for dialysis-dependent patients, is currently ongoing.

Events